Hepatitis Monthly

Published by: Kowsar

An Evaluation of the Usefulness of Extracorporeal Liver Support Techniques in Patients Hospitalized in the ICU for Severe Liver Dysfunction Secondary to Alcoholic Liver Disease

Mariusz Piechota 1 , * and Anna Piechota 2
Authors Information
1 Department of Anaesthesiology and Intensive Therapy Centre for Artificial Extracorporeal Kidney and Liver Support, Dr Wł. Biegański Regional Specialist Hospital, Łódź, Poland
2 Faculty of Economics and Sociology, Department of Insurance, University of Łódź, Łódź, Poland
Article information
  • Hepatitis Monthly: July 01, 2016, 16 (7); e34127
  • Published Online: July 2, 2016
  • Article Type: Research Article
  • Received: October 28, 2015
  • Accepted: June 13, 2016
  • DOI: 10.5812/hepatmon.34127

To Cite: Piechota M, Piechota A. An Evaluation of the Usefulness of Extracorporeal Liver Support Techniques in Patients Hospitalized in the ICU for Severe Liver Dysfunction Secondary to Alcoholic Liver Disease, Hepat Mon. 2016 ;16(7):e34127. doi: 10.5812/hepatmon.34127.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnote
References
  • 1. European Association for the Study of L. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012; 57(2): 399-420[DOI][PubMed]
  • 2. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012; 56 Suppl 1-45[DOI][PubMed]
  • 3. O'Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Alcoholic liver disease. Hepatology. 2010; 51(1): 307-28[DOI][PubMed]
  • 4. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol. 2003; 38(124-31)
  • 5. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol. 2005; 43(1): 142-8[DOI][PubMed]
  • 6. Catalina MV, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int. 2003; 23 Suppl 3: 39-43[PubMed]
  • 7. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006; 10(4)[DOI][PubMed]
  • 8. Pares A, Cisneros L, Salmerón JM, Mas A, Torras A, Caballeria J, et al. The molecular adsorbent recirculating system (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis. J Hepatol. 2002; 36(1): 150
  • 9. Pares A, Deulofeu R, Cisneros L, Escorsell A, Salmeron JM, Caballeria J, et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care. 2009; 13(1)[DOI][PubMed]
  • 10. Hassanein T, Tamsen MR, Petcharaporn L, Hassanemin R, Monson P, Baralak F. Extracorporeal Albumin Dialysis Improves Survival in Patients with Severe Alcoholic Hepatitis. Hepatol. 2012; 56
  • 11. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013; 57(3): 1153-62[DOI][PubMed]
  • 12. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012; 142(4): 782-789 e3[DOI][PubMed]
  • 13. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs. 1999; 23(1): 81-6[PubMed]
  • 14. Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, Kim WR. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol. 2010; 105(8): 1782-7[DOI][PubMed]
  • 15. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009; 373(9682): 2223-33[DOI][PubMed]
  • 16. Naveau S. [Current trend: alcoholic liver diseases]. Gastroenterol Clin Biol. 2006; 30(4): 550-3[PubMed]
  • 17. WHO. European Status Report on Alcohol and Health 2010. WHO Copenhagen: WHO Regional Office for Europe. 2010;
  • 18. Anderson HR, Baumburg B. Alcohol in Europe. 2006;
  • 19. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis. 2004; 24(3): 233-47[DOI][PubMed]
  • 20. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996; 23(5): 1025-9[DOI][PubMed]
  • 21. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997; 41(6): 845-50[PubMed]
  • 22. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995; 346(8981): 987-90[PubMed]
  • 23. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med. 1999; 48(4): 184-8[PubMed]
  • 24. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5): 1572-85[DOI][PubMed]
  • 25. Blakolmer K, Jain A, Ruppert K, Gray E, Duquesnoy R, Murase N, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000; 69(11): 2330-6[PubMed]
  • 26. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365(19): 1790-800[DOI][PubMed]
  • 27. Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol. 2015; 3(2): 109-16[DOI][PubMed]
  • 28. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation. 2001; 72(4): 619-26[PubMed]
  • 29. Haflidadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 2014; 14: 166[DOI][PubMed]
  • 30. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, et al. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology. 2003; 50(54): 2101-4[PubMed]
  • 31. Maddrey WC, Boitnott JK, Bedine MS, Weber FJ, Mezey E, White RJ. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978; 75(2): 193-9[PubMed]
  • 32. Bell H, Jahnsen J, Kittang E, Raknerud N, Sandvik L. Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scand J Gastroenterol. 2004; 39(9): 858-63[DOI][PubMed]
  • 33. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010; 51(5): 1675-82[DOI][PubMed]
  • 34. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000; 31(4): 864-71[DOI][PubMed]
  • 35. Monsanto P, Almeida N, Lrias C, Pina JE, Sofia C. Evaluation of MELD score and Maddrey discriminant function for mortality prediction in patients with alcoholic hepatitis. Hepatogastroenterology. 2013; 60(125): 1089-94[DOI][PubMed]
  • 36. Kadian M, Kakkar R, Dhar M, Kaushik RM. Model for end-stage liver disease score versus Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis. J Gastroenterol Hepatol. 2014; 29(3): 581-8[DOI][PubMed]
  • 37. Yang Y, Deng L, Li X, Shi Z, Chen D, Chen X, et al. Evaluation of the prognosis of fulminant viral hepatitis in late pregnancy by the MELD scoring system. Eur J Clin Microbiol Infect Dis. 2012; 31(10): 2673-8[DOI][PubMed]
  • 38. Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, et al. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis. 2008; 40(11): 882-9[DOI][PubMed]
  • 39. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004; 40(6): 897-903[DOI][PubMed]
  • 40. Brandsaeter B, Broome U, Isoniemi H, Friman S, Hansen B, Schrumpf E, et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl. 2003; 9(9): 961-9[DOI][PubMed]
  • 41. Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3): 797-805[DOI][PubMed]
  • 42. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol. 2005; 42(5): 700-6[DOI][PubMed]
  • 43. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005; 41(2): 353-8[DOI][PubMed]
  • 44. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002; 2: 2[PubMed]
  • 45. Piechota M. Hepatic encephalopathy in the course of alcoholic liver disease--treatment options in the intensive care unit. Anaesthesiol Intensive Ther. 2014; 46(1): 34-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments